Dapagliflozin Tablet, Film Coated
Product Images NDC 62332-393

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 62332-393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Dapagliflozin 1 Figure)

A scatter plot with dose-response curves showing cumulative 24-hour urinary glucose excretion (CFB) in grams versus Dapagliflozin dose in mg. Observed values for healthy subjects and subjects with Type 2 diabetes mellitus (T2DM) are plotted separately with fitted lines for each group illustrating dose-related increases in urinary glucose excretion.*

FDA Label Image

30 Tablets (Dapagliflozin 10 mg)

Dapagliflozin 10 mg film coated tablets label showing the dosage strength and count of 30 tablets. The label includes the NDC 62332-393-30, manufacturer's information listing Alembic Pharmaceuticals Inc., instructions to dispense the accompanying Medication Guide, Rx only designation, and storage guidelines. Barcode and batch details are also visible.*

FDA Label Image

Figure 4 (Dapagliflozin 4 Figure)

A line graph comparing the percentage of patients with an event over 60 months from randomization between Dapagliflozin Tablets and Placebo groups. The graph shows time on the x-axis (months) and patients with event percentage on the y-axis. Numbers of patients at risk for both groups are listed below the graph at various time points.*

FDA Label Image

Figure 5 (Dapagliflozin 5 Figure)

A Kaplan-Meier curve comparing the percentage of patients with events over 60 months from randomization between dapagliflozin tablets and placebo. The y-axis shows patients with events (%) and the x-axis shows time in months. Two lines depict event rates: one for dapagliflozin tablets and one for placebo, with placebo showing a higher event rate. A table below lists the number of patients at risk over time for each group.*

FDA Label Image

30 Tablets (Dapagliflozin 5 mg)

Dapagliflozin 5 mg film-coated tablets label from Alembic Pharmaceuticals Inc. The label includes NDC 62332-392-30 and states the tablet strength as 5 mg. It indicates a 30-tablet package and provides storage instructions along with manufacturer information and a barcode.*

FDA Label Image

Figure 2 (Dapagliflozin Figure2)

A line graph showing the adjusted mean change (%) from baseline in HbA1c levels over a 24-week study period. The graph compares three groups: Dapagliflozin tablets 10 mg plus Metformin, Dapagliflozin tablets 10 mg alone, and Metformin alone. The data include longitudinal measurements over weeks 0, 4, 8, 12, 16, 20, and 24, displaying decreases in HbA1c across all groups, with the combination treatment showing the greatest reduction. A smaller inset graph shows adjusted mean changes at week 24 with 95% confidence intervals.*

FDA Label Image

Figure 3 (Dapagliflozin Figure3)

A line graph comparing the percentage adjusted mean change in HbA1c from baseline over 24 weeks between placebo plus metformin and dapagliflozin 10 mg plus metformin treatment groups. The x-axis shows study weeks from 0 to 24, and the y-axis shows HbA1c change from baseline. Error bars for 24-week LOCF values with 95% confidence intervals are shown on the right side of the graph.*

FDA Label Image

Structure (Dapagliflozin Str)

Chemical structure of dapagliflozin, showing its molecular framework including hydroxyl groups, aromatic rings with chlorine substitution, and an ether-linked ethyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.